Tongfang Kontafarma Holdings Limited (1312.HK)
HKD 0.03
(4.17%)
HKD 0.03
(4.17%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 809.1 Million HKD | -9.5% |
| 2022 | 894.06 Million HKD | -6.97% |
| 2021 | 961.08 Million HKD | -4.76% |
| 2020 | 1 Billion HKD | -31.92% |
| 2019 | 1.48 Billion HKD | -29.2% |
| 2018 | 2.09 Billion HKD | 55.74% |
| 2017 | 1.34 Billion HKD | 112.28% |
| 2016 | 633.27 Million HKD | 35.97% |
| 2015 | 465.73 Million HKD | -36.47% |
| 2014 | 733.12 Million HKD | 4.22% |
| 2013 | 703.46 Million HKD | -0.17% |
| 2012 | 704.69 Million HKD | -2.84% |
| 2011 | 725.29 Million HKD | 60.66% |
| 2010 | 451.44 Million HKD | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q2 | 458.51 Million HKD | 0.0% |
| 2023 Q1 | 215.35 Million HKD | -51.39% |
| 2023 Q2 | 430.7 Million HKD | 100.0% |
| 2023 FY | 809.1 Million HKD | -9.5% |
| 2023 Q4 | 378.4 Million HKD | 100.0% |
| 2023 Q3 | 189.2 Million HKD | -56.07% |
| 2022 Q1 | 225.54 Million HKD | -55.15% |
| 2022 FY | 894.06 Million HKD | -6.97% |
| 2022 Q4 | 442.97 Million HKD | 100.0% |
| 2022 Q3 | 221.48 Million HKD | -50.9% |
| 2022 Q2 | 451.08 Million HKD | 100.0% |
| 2021 FY | 961.08 Million HKD | -4.76% |
| 2021 Q1 | 192.52 Million HKD | -35.38% |
| 2021 Q2 | 458.19 Million HKD | 137.99% |
| 2021 Q3 | 251.44 Million HKD | -45.12% |
| 2021 Q4 | 502.89 Million HKD | 100.0% |
| 2020 FY | 1 Billion HKD | -31.92% |
| 2020 Q1 | 227.85 Million HKD | 28.64% |
| 2020 Q2 | 711.17 Million HKD | 212.12% |
| 2020 Q4 | 297.96 Million HKD | 0.0% |
| 2019 Q2 | 1.3 Billion HKD | 264.84% |
| 2019 Q3 | 88.56 Million HKD | -93.21% |
| 2019 Q1 | 357.75 Million HKD | -24.75% |
| 2019 FY | 1.48 Billion HKD | -29.2% |
| 2019 Q4 | 177.12 Million HKD | 100.0% |
| 2018 Q2 | 571.41 Million HKD | 0.0% |
| 2018 Q4 | 475.44 Million HKD | 0.0% |
| 2018 FY | 2.09 Billion HKD | 55.74% |
| 2018 Q1 | 571.41 Million HKD | 55.92% |
| 2018 Q3 | 475.44 Million HKD | -16.79% |
| 2017 Q1 | 305.68 Million HKD | 54.98% |
| 2017 FY | 1.34 Billion HKD | 112.28% |
| 2017 Q4 | 366.48 Million HKD | 0.0% |
| 2017 Q3 | 366.48 Million HKD | 19.89% |
| 2017 Q2 | 305.68 Million HKD | 0.0% |
| 2016 Q2 | 119.4 Million HKD | 0.0% |
| 2016 Q4 | 197.23 Million HKD | 0.0% |
| 2016 Q3 | 197.23 Million HKD | 65.19% |
| 2016 Q1 | 119.4 Million HKD | 15.61% |
| 2016 FY | 633.27 Million HKD | 35.97% |
| 2015 Q2 | 129.59 Million HKD | 0.0% |
| 2015 Q3 | 103.27 Million HKD | -20.31% |
| 2015 Q4 | 103.27 Million HKD | 0.0% |
| 2015 FY | 465.73 Million HKD | -36.47% |
| 2015 Q1 | 129.59 Million HKD | -29.77% |
| 2014 Q3 | 184.52 Million HKD | 1.37% |
| 2014 Q4 | 184.52 Million HKD | 0.0% |
| 2014 Q2 | 182.03 Million HKD | 0.0% |
| 2014 Q1 | 182.03 Million HKD | -8.25% |
| 2014 FY | 733.12 Million HKD | 4.22% |
| 2013 Q3 | 198.39 Million HKD | 29.39% |
| 2013 FY | 703.46 Million HKD | -0.17% |
| 2013 Q1 | 153.33 Million HKD | -14.83% |
| 2013 Q2 | 153.33 Million HKD | 0.0% |
| 2013 Q4 | 198.39 Million HKD | 0.0% |
| 2012 FY | 704.69 Million HKD | -2.84% |
| 2012 Q3 | 180.04 Million HKD | 2.2% |
| 2012 Q2 | 176.17 Million HKD | 0.0% |
| 2012 Q4 | 180.04 Million HKD | 0.0% |
| 2012 Q1 | 176.17 Million HKD | 0.0% |
| 2011 Q2 | 181.32 Million HKD | 0.0% |
| 2011 Q4 | 176.17 Million HKD | -2.84% |
| 2011 FY | 725.29 Million HKD | 60.66% |
| 2011 Q1 | 181.32 Million HKD | 0.0% |
| 2011 Q3 | 181.32 Million HKD | 0.0% |
| 2010 Q4 | 181.32 Million HKD | 60.66% |
| 2010 Q1 | 112.86 Million HKD | 0.0% |
| 2010 Q2 | 112.86 Million HKD | 0.0% |
| 2010 FY | 451.44 Million HKD | 0.0% |
| 2010 Q3 | 112.86 Million HKD | 0.0% |
| 2009 Q4 | 112.86 Million HKD | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Pak Fah Yeow International Limited | 259.15 Million HKD | -212.206% |
| Grand Pharmaceutical Group Limited | 10.52 Billion HKD | 92.316% |
| Extrawell Pharmaceutical Holdings Limited | 59.09 Million HKD | -1269.094% |
| Wai Yuen Tong Medicine Holdings Limited | 783.88 Million HKD | -3.218% |
| Qianhai Health Holdings Limited | 961.29 Million HKD | 15.831% |
| Lee's Pharmaceutical Holdings Limited | 1.05 Billion HKD | 23.164% |
| Essex Bio-Technology Limited | 1.7 Billion HKD | 52.588% |
| PuraPharm Corporation Limited | 406.85 Million HKD | -98.867% |
| SSY Group Limited | 6.46 Billion HKD | 87.481% |
| JBM (Healthcare) Limited | 648.41 Million HKD | -24.782% |
| Jacobson Pharma Corporation Limited | 1.46 Billion HKD | 44.876% |
| China Resources Pharmaceutical Group Limited | 270.39 Billion HKD | 99.701% |